A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.

NCT Number	NCT07711418
Lead Sponsor	Nektar Therapeutics
Conditions	Moderate-to-Severe Atopic Dermatitis
Enrollment	510 participants
Start Date	2026-08
Primary Completion	2028-06 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-17